Skip to main content

Aegle Therapeutics Corp.

October 18, 2023
Franciscan B
Gene/Cell Therapy
Aegle Therapeutics is a clinical stage biotech company with a platform technology focused on rare diseases. Aegle first product, AGLE-102, is a compositive of nanoparticles called extracellular vesicles (“EVsâ€') that are produced by stem cells. These EVs contain active biomolecules including proteins and nucleic acids which not only promote regenerative healing but are anti-inflammatory and immunomodulating as well. Aegle is currently enrolling patients in a phase 1/2a study using AGLE-102 to prevent wound progression and scarring (funded by the DOD) and will launch a phase 1/2a study in Q4 2023 for the treatment of epidermolysis bullosa. Aegle's technology has application in a broad array of therapeutic areas including immunology (preclinical data in GvHD), dermatology and orthopedic.
Shelley Hartman - Aegle Therapeutics Corp.